Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) is a Healthcare company (Biotechnology) with a market capitalization of $3.1B. The Maz Rating grades it against the other companies in its sector.
About three months ago (July 2, 2026), Acadia Pharmaceuticals Inc. had a Maz Rating of 4.41 out of 5 (A, Strong Buy), ranked against the other companies in its sector. Its strongest factor then was Financial Health (4.77), among the strongest in its sector; its weakest was Valuation (2.44), more expensive than most of its sector. The other factors: Profitability 4.47 (above most of its sector); Momentum 3.34 (around the middle of its sector); Growth 3.12 (around the middle of its sector). The current rating is for members: log in to see it.
At $18.14, Acadia Pharmaceuticals Inc. trades at 8.5x trailing earnings, 2.6x sales and 2.2x book value, with an EV/EBITDA of 19.3. Over the last twelve months it generated about $1.2B of revenue and $370M of net income. It runs a gross margin of 90.5%, an operating margin of 10.2% and a net margin of 30.1%. It shows return on equity of 28.0%, return on invested capital of 8.3% and a free cash flow yield of 3.5%. On the balance sheet: a debt-to-equity ratio of 0.05 and a current ratio of 3.82. Over the past 52 weeks the share price ranged from $15.86 to $30.96, with a beta of 0.89.
Acadia Pharmaceuticals Inc. does not currently pay a dividend.
37 Wall Street analyst ratings cover the stock: 25 Buy, 11 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.